Predictive Oncology Valuation
| POAIDelisted Stock | USD 5.95 0.00 0.00% |
At this time, the company appears to be overvalued. Predictive Oncology holds a recent Real Value of $5.65 per share. The prevailing price of the company is $5.95. Our model determines the value of Predictive Oncology from analyzing the company fundamentals such as Return On Equity of -7.46, current valuation of 21.66 M, and Shares Owned By Insiders of 4.92 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Predictive Oncology's price fluctuation is risky at this time. Calculation of the real value of Predictive Oncology is based on 3 months time horizon. Increasing Predictive Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Predictive Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Predictive Stock. However, Predictive Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.95 | Real 5.65 | Hype 5.88 | Naive 5.57 |
The intrinsic value of Predictive Oncology's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Predictive Oncology's stock price.
Estimating the potential upside or downside of Predictive Oncology helps investors to forecast how Predictive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Predictive Oncology more accurately as focusing exclusively on Predictive Oncology's fundamentals will not take into account other important factors: About Predictive Oncology Valuation
An absolute valuation paradigm, as applied to Predictive Stock, attempts to find the value of Predictive Oncology based on its fundamental and basic technical indicators. By analyzing Predictive Oncology's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Predictive Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Predictive Oncology. We calculate exposure to Predictive Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Predictive Oncology's related companies.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Predictive Stock
If you are still planning to invest in Predictive Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Predictive Oncology's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |